DeepCure, a Boston, MA-based leader in developing novel, small-molecule therapeutics using the world’s largest AI drug discovery engine, announced the closing of a $40 million Series A financing.
The round was led by Morningside Ventures, with participation from existing investors TLV Partners, Sapir Venture Partners, and Benon Group Ltd. The Company has raised a total of $47 million in financing since its inception.
The proceeds from the Series A financing will be used to expand DeepCure’s pipeline with five additional oncology programs and develop an automated robotic wet lab to fulfill its vision of developing drugs that are fully designed, synthesized, and tested by AI.
The funding will also be used to double the headcount of its current drug discovery scientists and technologists next year, including a global expansion with the launch of two new sites in Greece and Israel.
Round: Series A
Funding Month: November 2021
Lead Investors: Morningside Ventures
Additional Investors: TLV Partners, Sapir Venture Partners, and Benon Group Ltd
Company Website: https://deepcure.ai/
Software Category: End-to-end drug discovery platform
About the Company: Deepcure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists, and biologists. Using an end-to-end drug discovery platform and automated robotic wet lab, the Company is developing a novel pipeline of precision small molecules across many different therapeutic indications. DeepCure’s founding team includes some of the industry’s preeminent researchers and technologists. Our vision is to use AI-driven discovery to create better small molecules therapeutics and faster cures for every disease-relevant protein target. DeepCure is based in Boston, MA.